ERBB2 and metastatic neoplasm: On completion of search, following information was tabulated in the predesigned excel chart – sex, de novo or secondary carcinoma, location, size of primary, clinical nodal involvement, metastatic disease at presentation if any, pathological information (pathological lymph node status, androgen receptor expression, Her2/neu over expression, PI3K mutation), adjuvant treatment received, duration of progression-free survival (PFS), overall survival (OS), site of recurrence and salvage treatment.